Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE: Aspirin to Prevent VTE in Advanced Germ Cell Tumors
NCT06866964Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2025
- Primary completion
- Aug 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of aspirin in venous thromboembolism (VTE), sponsored by Wake Forest University Health Sciences. Started Aug 2025; status: recruiting.
02
Drugs
aspirin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06866964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866964.